| | | Funny how the FDA inspected Wang's lab, his Elisa machine, time stamped data, spreadsheets, plate reading, image scanning procedures, etc. and came to an entirely different conclusion. IMMU investors know all about 483 inspections. The FDA does not mess around-- and they were looking specifically for evidence of manipulation in Wang's P2b biomarkers. And unlike the SEC, they were not motivated by $$$.
As for P2b cognition scores using CANTAB, a rather coarse measure reserved mostly for brain trauma victims, Cassava Sciences did in fact disclose in the company presentation the removal of outliers both good and bad, which is standard procedure... just not in the PR. However, the PR clearly states that the study is merely looking for directional trends "due to limitations around study size" and obviously study length. 28 days? Pfff.
Regardless, none of this has anything to do with the 220-patient cognition results over 24 months. That data is uncorrupted and untouchable. Incidentally, Dr. Wang analyzed the biomarkers in that study as well-- just 25 patients and not a focus of the study-- so you can be sure the SEC and DOJ had their snouts all up up in that. And found nothing. As a matter of fact, THIS biomarker data at six months in tandem with -4.96 ADAS-Cog at twelve months is the Holy Grail, not just for me but the FDA. All we need is placebo.
Message 34746590 |
|
